PNC Financial Services Group’s Prelude Therapeutics PRLD Stock Holding History

PNC Financial Services Group’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.89K	Sell	738 -433	-37%	-$2.12K	﹤0.01%	4719
2026 Q2	$6.24K	Hold	1,171	–	–	﹤0.01%	4306
2026 Q1	$4K	Hold	1,171	–	–	﹤0.01%	4362
2025 Q4	$3.4K	Hold	1,171	–	–	﹤0.01%	4376
2025 Q3	$1.69K	Sell	1,171 -9	-0.8%	-$9	﹤0.01%	4552
2025 Q2	$956	Sell	1,180 -12	-1%	-$10	﹤0.01%	4574
2025 Q1	$915	Buy	1,192 +1,128	+1,763%	+$1.05K	﹤0.01%	4539
2024 Q4	$82	Hold	64	–	–	﹤0.01%	4718
2024 Q3	$132	Hold	64	–	–	﹤0.01%	4707
2024 Q2	$244	Buy	+64	New	+$260	﹤0.01%	4635

Other funds holding PRLD

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

PNC Financial Services Group's PRLD Position: Q3 2026 in Review

PNC Financial Services Group reduced its Prelude Therapeutics (PRLD) stake by 37% in Q3 2026, selling an estimated $2.12K and leaving 738 shares worth $2.89K. The position accounts for ﹤0.01% of the portfolio, ranked #4719.

PNC Financial Services Group first reported a position in PRLD in Q2 2024 and has held it in 10 quarters since. The position peaked at $6.24K in Q2 2026. 59 funds tracked by Wall St. Rank hold PRLD as of Q3 2026.

PNC Financial Services Group held 738 shares of Prelude Therapeutics worth $2.89K as of Q3 2026.
PNC Financial Services Group sold 433 Prelude Therapeutics shares in Q3 2026, an estimated $2.12K.
Prelude Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4719 holding.
PNC Financial Services Group first reported a position in Prelude Therapeutics in Q2 2024 and has held it in 10 quarters since.
PNC Financial Services Group's Prelude Therapeutics position peaked at $6.24K in Q2 2026.
59 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.